NL-OMON27294CompletedNot Applicable
Risk adapted treatment of acute myelocytic leukemia (AML).
Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON) P/a HOVON Data CenterErasmus MC - Daniel den HoedPostbus 52013008 AE RotterdamTel: 010 4391568Fax: 010 4391028e-mail: hdc@erasmusmc.nl0 sites1,105 target enrollmentStarted: TBDLast updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 1,105
Study Overview
Brief Summary
- G.E. de Greef, W.L. van Putten, M. Boogaerts, P.C. Huijgens, L.F. Verdonck, E. Vellenga, M. Theobald, E. Jacky and B. Löwenberg; The Dutch-Belgian Hemato-Oncology Co-operative Group HOVON; The Swiss Group for Clinical Cancer Research SAKK. Criteria for defining a complete remission in acute myeloid leukaemia revisited. An analysis of patients treated in HOVON-SAKK co-operative group studies. British Journal of Haematology, 128(2), 184-191. 2005 (also data of HOVON 4 and 4A);
2. D.A. Breems, W.L. van Putten, P.C. Huijgens, G.J. Ossenkoppele, G.E. Verhoef, L.F. Verdonck, E. Vellenga, G.E. de Greef, E. Jacky, J. van der Lelie, M.A. Boogaerts and B. Löwenberg. Prognostic Index for Adult Patients With Acute Myeloid Leukemia in First Relapse. Journal of Clinical Oncology, 2005 Jan 4; [Epub ahead of print] (also data of HOVON 4 and 4A);
3. B. Löwenberg, W. van Putten, M. Theobald, J. Gmür, L. Verdonck, P. Sonneveld, M. Fey, H. Schouten, G. de Greef, A. Ferrant, T. Kovacsovics, A. Gratwohl, S. Daenen, P. Huijgens, M. Boogaerts; Dutch-Belgian Hemato-Oncology Cooperative Group; Swiss Group for Clinical Cancer Research. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. The New England Journal of Medicine, 349(8), 743-752. 2003;
4. E. Vellenga, W.L.J. van Putten, M.A. Boogaerts, S.M.G.J. Daenen, G.E.G. Verhoef, A. Hagenbeek, A.R. Jonkhoff, P.C. Huijgens, L.F. Verdonck, J. van der Lelie, H.C. Schouten, J. Gmür, P. Wijermans, A. Gratwoh, U. Hess, M.F. Fey and B. Löwenberg. Peripheral blood stem cell transplantation as an alternative to autologous marrow transplantation in the treatment of acute myeloid leukemia. Bone Marrow Transplantation, 23, 1279-1282. 1999.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •First randomization:
- •1. Patients with newly diagnosed de novo AML (including all cytological subtypes M0-M7);
Exclusion Criteria
- •First randomization:
- •1. Patients with a concurrent active malignancy, except stage I cervix carcinoma and basocellular carcinoma;
Investigators
Similar Trials
Completed
Not Applicable
Risk adapted treatment of Acute Myelocytic Leukaemia (AML)Acute Myeloid Leukaemia (AML)CancerISRCTN76815071Dutch Haemato-Oncology Association (Stichting Hemato-Oncologie Volwassenen Nederland) (HOVON) (Netherlands)1,105
Active, not recruiting
Phase 3
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down SyndromeDown SyndromeMyeloid Leukemia Associated With Down SyndromeMyeloproliferative NeoplasmAcute Myeloid LeukemiaMyelodysplastic SyndromeNCT02521493Children's Oncology Group280
Unknown
Not Applicable
Risk-stratified Therapy Based on Molecular Cytogenetic Aberration and Treatment Response in AMLRisk-directed TherapyCytogenetic AbnormalityMolecular AbnormalityMRDNCT03620955Nanfang Hospital, Southern Medical University1,000
Completed
Phase 3
Risk-Adapted Therapy of Acute Myeloid Leukemia of Adults (18-60 Years) According to the Cytogenetic ResultAcute Myeloid LeukemiaNCT00146120University of Ulm400
Completed
Phase 2
Prospective Study of Mylotarg and G-CSF in Acute Myeloid Leukemia TreatmentNovo Acute Myeloid LeukemiaNCT01698879Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias46